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Abstract. 
 
Simple epithelia express keratins 8 (K8) and 
18 (K18) as their major intermediate filament (IF) pro-
teins. One important physiologic function of K8/18 is to 
protect hepatocytes from drug-induced liver injury. Al-
though the mechanism of this protection is unknown, 
marked K8/18 hyperphosphorylation occurs in associa-
tion with a variety of cell stresses and during mitosis. 
This increase in keratin phosphorylation involves mul-
tiple sites including human K18 serine-(ser)52, which is 
a major K18 phosphorylation site. We studied the sig-
nificance of keratin hyperphosphorylation and focused 
on K18 ser52 by generating transgenic mice that over-
 
express a human genomic K18 ser52
 
®
 
ala mutant 
(S52A) and compared them with mice that overexpress, 
at similar levels, wild-type (WT) human K18. Abroga-
tion of K18 ser52 phosphorylation did not affect fila-
ment organization after partial hepatectomy nor the 
ability of mouse livers to regenerate. However, expo-
sure of S52A-expressing mice to the hepatotoxins, 
griseofulvin or microcystin, which are associated with 
K18 ser52 and other keratin phosphorylation changes, 
resulted in more dramatic hepatotoxicity as compared 
with WT K18-expressing mice. Our results demonstrate 
that K18 ser52 phosphorylation plays a physiologic role 
in protecting hepatocytes from stress-induced liver in-
jury. Since hepatotoxins are associated with increased 
keratin phosphorylation at multiple sites, it is likely that 
unique sites aside from K18 ser52, and phosphorylation 
sites on other IF proteins, also participate in protection 
from cell stress.
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I
 
ntermediate
 
 filament (IF)
 
1
 
 proteins are one of the
three major cytoskeletal protein groups, that also in-
clude microfilaments and microtubules (reviewed in
reference 14, 34, 49). A comparison of the three major cy-
toskeletal protein groups shows several distinguishing
unique features of IF proteins: they have nuclear (i.e., the
lamins) and many cytoplasmic members, their cytoplasmic
members appear to be expressed only in higher eucaryotes
in a tissue preferential manner, and mutations of IF pro-
teins cause a variety of human diseases (15). Among the
diverse IF protein family, the keratin subgroup is the larg-
 
est and is specifically expressed in epithelial cells (44).
Aside from the ÒhardÓ keratins that are found in epider-
mal appendages (e.g., hair and nails), the ÒsoftÓ keratins
(K) consist of 
 
.
 
20 members that are divided into rela-
tively basic type II (K1-K8) and acidic type I (K9-K20)
keratins (44). All epithelial cells express at least one type I
and one type II keratin that associate, noncovalently, to
form extended filamentous arrays. In general, epithelial
cells express a dominant unique keratin pair depending on
the epithelial cell type. For example, glandular epithelia
express K8 and K18 (with variable levels of K19 and K20),
whereas keratinocytes preferentially express K5/14 basally
and K1/10 suprabasally. Although keratin function(s) re-
main poorly understood, one clear function is to provide
mechanical integrity to cells including those in epidermis
(15), cornea (19) and liver (46). This was clearly demon-
strated by the phenotypes of several human diseases that
are caused by keratin mutations and by several transgenic
animal models that express mutant keratins (15, 43, 46).
All IF proteins have a prototype structure consisting of
a central coiled-coil 
 
a
 
-
 
helix (310Ð350 amino acids) that is
surrounded by globular NH
 
2
 
-terminal head and COOH-
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1. 
 
Abbreviations used in this paper: 
 
Emp, Empigen BB; GF, griseofulvin;
IF, intermediate filament(s); K, keratin; MLR, microcystin LR; pS, phos-
pho-serine; PVDF, polyvinylidene difluoride; S52A, transgenic mice that
overexpress ser52
 
®
 
ala K18; TG2, transgenic mice that overexpress wild-
type human K18; WT, wild-type.
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terminal tail domains of variable length (14, 34, 49). The
globular end domains provide most of the structural het-
erogeneity among IF proteins and contain all currently
known phosphorylation and glycosylation sites, in contrast
with the nonmodified rod domain (reviewed in 18, 26, 47).
The exclusive presence of keratin phosphorylation within
the structurally heterogeneous head and tail domains sug-
gests that this modification may play a regulatory role in
the presumed tissue-specific function of these proteins. In
the case of K18, ser52 is its major phosphorylation site
during interphase. K18 ser52 phosphorylation is highly dy-
namic, increases two to three times during mitosis, and ap-
pears to be important for filament reorganization (23, 37).
A potential role for K18 ser52 in filament organization
was implicated based on transfection of a K18 ser52
 
®
 
ala
mutant, which results in a keratin filamentous array that is
twofold less able to reorganize its filaments, after treat-
ment with colcemid or okadaic acid, as compared with WT
K18-transfected cells (23). Several other K8 and K18 phos-
phorylation sites have been identified including K18 ser33
that regulates binding to 14-3-3 proteins (30), K8 ser23
that is highly conserved among all type II keratins (24), K8
ser431 that is phosphorylated by MAP kinase upon EGF
stimulation (24), and K8 ser73 that becomes phosphory-
lated during mitosis, cell stress, and apoptosis (40).
Two observations led us to investigate keratin phosphor-
ylation in transgenic mice in situ. First, disruption of K8/18
filaments in transgenic mice after expression of a domi-
nant negative K18 arg89
 
®
 
cys results in hepatocyte keratin
IF collapse in association with chronic hepatitis (25) and
increased susceptibility to drug-induced liver injury (27).
This, coupled with the abnormal liver phenotype of K8-
null mice (4, 5, 41) and mice that express K14 ectopically in
the liver (3) indicated that K8/18 play an important role in
helping hepatocytes cope with cell stress. Such a functional
role for keratin was not discernible before the use of trans-
genic animal models as was done first for K14 (54) and
subsequently several other IF proteins (15), and the initial
identification of keratin mutations in the human blistering
skin disease epidermolysis bullosa simplex (6, 13, 33). Sec-
ond, a variety of stress conditions in cultured cells and
intact animals are associated with significant K8/18 hy-
perphosphorylation, including rotavirus infection or heat
stress in cultured cells (38), apoptosis (8, 28), and drug-
induced liver injury using the anti-fungal agent griseoful-
vin (27) or the phosphatase inhibitor microcystin LR (MLR;
45, 51, 52). Given that ser52 is a major K18 phosphoryla-
tion site, we sought to determine its physiologic function
by generating transgenic mice that overexpress a K18
ser52
 
®
 
ala mutant and comparing the phenotype and ker-
atin phosphorylation in these mice with the well described
transgenic mice that overexpress WT human K18 (termed
TG2; references 1, 25, 27). This represents the first report
that we are aware of that utilizes transgenic animals to
study the significance of a single phosphorylation site of a
protein.
 
Materials and Methods
 
Cell Culture, Antibodies, and Reagents
 
NIH-3T3 (mouse fibroblast) and HT29 (human colon) cells (American
Type Culture Collection, Manassas, VA) were cultured as recommended
by the supplier. Antibodies (Ab) used were: L2A1 mouse mAb that rec-
ognizes human K18 without cross-reacting with mouse keratins (11, 25);
Troma I rat mAb that recognizes mouse K8 (Developmental Studies Hy-
bridoma Bank, University of Iowa, Iowa City, IA); rabbit Ab 8592 that
was raised against human K8/18 (25); rabbit Ab 3055 that recognizes
phospho-ser52 (pS52) of human K18 and does not cross-react with the
corresponding phosphorylation site in mouse K18 that has a different anti-
genic context (37); rabbit Ab 8250 that recognizes human K18 pS33 and
does cross-react with the equivalent mouse phosphorylation site (30);
mAb LJ4 that recognizes K8 pS73 (40); anti-mouse K18 (provided by
Robert Oshima); and anti-plectin and anti-desmoplakin Abs (provided by
Harald Herrmann and Manijeh Pasdar, respectively). Other reagents used
were: microcystin-LR (Alexis Corp., San Diego, CA), griseofulvin (GF;
Sigma Chemical Company, St. Louis, MO), calf intestine alkaline phos-
phatase (Boehringer Mannheim, Indianapolis, IN), orthophosphate (
 
32
 
PO
 
4
 
;
Dupont-New England Nuclear, Wilmington, DE), Empigen (Emp) BB
detergent (Calbiochem-Novabiochem Corp., La Jolla, CA), collagenase
type I (Worthington Biomedical Corp., Freehold, NJ), Transformerª
mutagenesis kit (CLONTECH Laboratories, Palo Alto, CA), and pow-
dered Lab Diet (PMI Feeds Inc., St. Louis, MO).
 
Transgene Construct and Generation of
Transgenic Lines
 
The human K18 cDNA ser52 codon (AGC) was mutated to a GCC (ala)
codon in a pBluescript SK
 
1
 
 plasmid using the Transformer kit as recom-
mended by the manufacturer. Confirmation of the mutation was done by
sequencing both strands of the mutated region. The mutant cDNA was
then digested with AlwN I to generate a 250-bp fragment that was then
substituted for the corresponding wild-type segment of exon 1 in a 10-kb
genomic K18 clone (provided by Dr. Robert Oshima, The Burnham Insti-
tute, La Jolla, CA), exactly as we had done in generating the arg89
 
®
 
cys
K18 genomic mutant (25). The 10-kb K18 ser52
 
®
 
ala genomic DNA was
injected into pronuclei of fertilized FVB/N mouse eggs. Progeny mice
carrying the human K18 gene were then chosen, after PCR screening,
followed by breeding to select for germline transmission using stan-
dard methods. Two mouse lines (S52A
 
1
 
 and S52A
 
2
 
) that express K18
ser52
 
®
 
ala were expanded and used for subsequent studies. The control
mice that were used (TG2 mice) overexpressed the wild-type 10-kb ge-
nomic K18 (1, 25, 27). PCR screening of mouse tail genomic DNA for the
presence of human K18 involved amplification of a 270-bp fragment that
corresponds to the COOH-terminal region of K18. The primers used
were: (
 
1
 
) 5
 
9
 
-CAGAAGGCCAGCTTGGAGAAC-3
 
9
 
 and (
 
2
 
) 5
 
9
 
-ATC-
TCCTGATCCCAGCACGTG-3
 
9
 
. All mice were housed in the same
room with standard infection control precautions.
 
Transgenic Mice, Liver and Serum Testing, and
Partial Hepatectomy
 
For all transgenic mouse hepatectomy and liver toxicity experiments, age
(all 
 
.
 
6 wk old, no more than 2 wk difference in age among the various
groups) and sex-matched mice were weighed just before use. Liver and
blood were collected after killing the mice using CO
 
2
 
 inhalation, then
bleeding via intracardiac puncture (0.5Ð1.0 ml). The liver was them imme-
diately harvested. Serum was analyzed from TG2 and S52A
 
1
 
 and S52A
 
2
 
control diet-fed mice (8 mice/line), GF-fed TG2 and S52A
 
1 
 
mice (10 mice/
line), MLR-treated mice (10 mice/line) for creatinine, glucose, total pro-
tein, alkaline phosphatase, albumin, triglycerides, cholesterol, total biliru-
bin, and alanine and aspartate aminotransferases. Partial hepatectomy
was done by removing the lateral, left, and right median lobes, as de-
scribed (55, 56) from TG2, S52A
 
1
 
 and S52A
 
2
 
 mice (16 mice/per transgenic
line). Mice were then killed 24 h (4 mice/line), 48 h (6 mice/line), and 72 h
(6 mice/line) afterwards and the livers were processed as below. For the
hepatectomy experiments, sham-hepatectomized mice (i.e., mice that had
anesthesia, an abdominal wall and peritoneal incision, exposure of the
liver then closure of the incisions) from each transgenic line served as con-
trols. Resected livers (from control diet-fed, sham-hepatectomized, post-
hepatectomy, GF-fed, or MLR-administered) were cut into several pieces
depending on the experiment and used for one or more of the following:
(
 
a
 
) fixation with 10% formalin followed by paraffin embedding, section-
ing, then hematoxylin and eosin staining (done by Histo-tec Laboratory,
Hayward, CA), (
 
b
 
) snap freezing in O.C.T. compound, sectioning then fix-
ing briefly in cold acetone for subsequent immunofluorescence staining,
(
 
c
 
) snap freezing in liquid nitrogen for subsequent biochemical analysis, 
Ku et al. 
 
Keratin Phosphorylation and Liver Injury
 
2025
 
and (
 
d
 
) cutting into small fragments then metabolic labeling with 
 
32
 
PO
 
4
 
 in
phosphate-free medium. Liver perfusion was performed as described (12)
using 0.025% collagenase type I, and hepatocyte viability was determined
using trypan blue exclusion.
 
Griseofulvin and Microcystin-LR Experiments
 
A pilot experiment was initially done using TG2, S52A
 
1
 
, and S52A
 
2
 
 mice
that were fed powered diet 
 
6
 
1.25% GF (6 mice/group). Since both S52A
 
1
 
and S52A
 
2
 
 mice gave similar results in terms of having a worse histologic
score upon GF feeding as compared with TG2 mice, we only used the
S52A
 
1
 
 for subsequent experiments. Mice (10/line) were then fed control
or GF-supplemented diet for 17 d followed by isolation, weighing then
processing of the livers as described above. Alternatively, mice were fed
control or GF-containing diet for 2, 5, or 8 d (2 mice/line) followed by the
processing of the livers. For the MLR experiments, pilot experiments
were carried out to determine the optimal dose that does not cause rapid
lethality. A dose of 30 
 
m
 
g/Kg was chosen, and as found for the GF experi-
ments, the S52A
 
1
 
 and S52A
 
2
 
 had a worse histology than the TG2 mice that
led us to use the S52A
 
1
 
 line for the subsequent quantitative experiments.
Mice (10/line) from each group were given 30 
 
m
 
g/Kg of MLR intraperito-
neally, followed by processing of the livers after 195 min. MLR was pre-
pared in dimethylsulfoxide, as a 1 mg/ml stock solution, then diluted in
PBS (10 mM sodium phosphate/0.15 M NaCl, pH 7.4).
 
Histology Grading and Statistical Analysis
 
All histology slides were examined by a pathologist (S.A. Michie) without
knowledge of the treatment, diet, or transgenic line. Grading of the GF-
related slides was done by counting the number of necrotic cells in a 20
 
3
 
field (10 fields per slide) and is presented as a necrosis score. Grading of
the MLR-related slides was done by estimating the extent of vacuolization
(
 
vacuolization score
 
) and area of hemorrhage/necrosis (
 
hemorrhage score
 
).
The vacuole score was estimated by assigning a 0 to 3
 
1
 
 score depending
on the percentage of vacuole volume as compared with overall hepatocyte
cytoplasmic volume such that: 0
 
 5 ,
 
10%, 1
 
1 5 
 
10Ð29%, 2
 
1 5 
 
30Ð49%,
and 3
 
1 5 $
 
50%. The hemorrhage score was estimated by assigning a 0 to
3
 
1
 
 score depending on extent of the hemorrhage and necrosis: 0
 
 5 
 
no ne-
crosis, 1
 
1 5 
 
small foci (mostly midzonal), 2
 
1 5 
 
confluent areas, and 3
 
1 5
 
diffuse hemorrhage and necrosis with rare intact islands of hepatocytes.
All scores and laboratory parameters are expressed as means 
 
6
 
SD. The
StudentÕs 
 
t
 
 test and nonparametric Wilcoxon method were used to calcu-
late the statistical significance between the means. Statistical analysis was
performed using JMP version 3.1 (SAS Institute Inc., Cary, NC).
 
Keratin Isolation, Immunoprecipitation, and
Other Methods
 
Liver pieces (
 
z
 
3 
 
3
 
 4 
 
3
 
 4 mm) were used to isolate keratins exactly as de-
scribed previously, either by immunoprecipitation (26) or high salt extrac-
tion (2, 25) except that NaF and sodium pyrophosphate were not added to
the solubilization buffer. For immunoprecipitation, liver pieces were solu-
bilized in 1% Emp or 1% NP-40 in PBS containing a protease/phos-
phatase inhibitor cocktail (25). Dephosphorylation of keratin immunopre-
cipitates was done with alkaline phosphatase (20 units/
 
m
 
l stock enzyme
mix) using 20 units in 20 
 
m
 
l of buffer (supplied by the manufacturer with
the enzyme) for 1 h (30
 
8
 
C) followed by washing 2
 
3
 
 with 1% NP-40 in
PBS. SDS-PAGE was done using 10% acrylamide gels (31). Radiolabel-
ing of NIH-3T3 or HT29 cells, or liver tissue fragments (250 
 
m
 
Ci/ml) was
done in 5 ml or 2 ml, respectively, of phosphate free RPMI-1640 media
containing 10% dialyzed FCS and 1Ð2% normal medium. Immunoblotting
(53) was done by transferring immunoprecipitates or total cell lysates (sol-
ubilized in 2% SDS/5% glycerol-containing Laemmli sample buffer) to
polyvinylidene difluoride (PVDF) membranes followed by blotting with
1:1,000 dilution of anti-keratin antibodies then visualization of the reac-
tive bands using enhanced chemiluminescence. Tryptic phosphopeptide
mapping of K18 that was purified by immunoprecipitation from 
 
32
 
PO
 
4
 
-
prelabeled detergent solubilized HT29 or transfected NIH-3T3 cells or
mouse freshly isolated liver fragments was done exactly as described (7).
IEF of the keratin precipitates (39) was done using a Mini-PROTEAN II
apparatus (BioRad Laboratories, Cambridge, MA) and an ampholine pH
mix of 3-10 and 5-7 as recommended by the manufacturer. Immunofluo-
rescence staining was done as described (26).
Comparative quantitation of keratin protein levels and phosphoryla-
tion was done using densitometric scanning of Coomassie-stained gels, or
 
by immunoblotting of serial dilutions of total liver tissue homogenates
using anti-pankeratin or anti-phosphokeratin antibodies. Northern blot
analysis was done using total liver RNA.
 
Results
 
Characterization of Transgenic Mice That Overexpress 
Human K18 ser52
 
®
 
ala
 
To address the physiologic function of keratin phosphory-
lation, we targeted a specific keratin phosphorylation site
in the context of an intact transgenic mouse. Our hypothe-
sis was that transgene expression of a keratin that is mu-
tated at a particular phosphorylation site may clarify the
potential role of keratin phosphorylation during mitosis
and/or in providing protection from drug-induced liver in-
jury. This hypothesis is based on the increase in K8/18
phosphorylation that is observed in association with a
variety of cell stresses in mice and cultured cells (26, 47).
To test this hypothesis, we generated a genomic K18
ser52
 
®
 
ala mutant and injected it into mouse embryos
then selected two lines (S52A
 
1
 
 and S52A
 
2
 
). The wild-type
(WT) 10-kb genomic K18 construct that we used to gener-
ate the point mutation was identical to what we used pre-
viously to generate a genomic K18 arg89
 
®
 
cys, which af-
forded tissue specific overexpression of human K18 that
paralleled that of the endogenous mouse K18 (25). For
comparison, and to serve as a control for WT human K18
overexpression, we used the well-characterized TG2 mice
that overexpress WT human K18 (1, 25). To isolate the
overexpressed human keratin, we used mAb L2A1 that
recognizes human K18 and does not cross-react with
mouse keratins (25). As shown in Fig. 1 
 
A
 
, mAb L2A1 im-
munoprecipitated nearly equal levels of keratins from liv-
ers of TG2 mice and mice from the two S52A transgenic
lines. As would be expected, immunoblotting of these pre-
cipitates with the previously described Ab 3055, which
specifically recognizes an epitope that contains human
phospho-ser52 (pS52; reference 37), showed binding only
to K18 from TG2 mice but not to K18 from S52A mice
(Fig. 1 
 
A
 
).
The relative levels of keratin expression were compared
in the livers of the transgenic lines and normal nontrans-
genic FVB/N mice by examining the total keratin pool us-
ing high salt extraction (Fig. 1 
 
B
 
) and total liver homoge-
nates (not shown). In TG2 mice, 
 
z
 
80% of the type I
keratins (i.e., the total human ectopic and endogenous
mouse K18) is human K18 whereas in the S52A mice
 
z
 
70% of the total keratin is human K18. Both S52A lines
express similar human K18 levels that in turn are slightly
lower than those noted in TG2 mice. The endogenous lev-
els of mouse K18 in TG2 and S52A mice, relative to wild-
type mice, are decreased in proportion to the increased
levels of ectopic human K18 such that the total type I ker-
atins remains essentially constant (not shown). Overall
and upon normalization of protein levels, type II keratin
levels are also similar in TG2, S52A, and wild-type mice.
Assignment of individual keratin bands was done by im-
munoblotting with anti-human and -mouse keratin-spe-
cific antibodies (e.g., Fig. 1 
 
B
 
 and data not shown). The
similarity of the keratin protein levels was also supported
by the transgene copy number and by Northern blot analy- 
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sis to quantitate human K18 mRNA levels (not shown).
The correlation between copy number, RNA and protein
levels indicate that the S52A mutation does not have a sig-
nificant effect on keratin protein turnover.
As part of the initial characterization of the phenotype
of the S52A mice, we examined the histology and keratin
immunofluorescence staining pattern of simple epithelial
organs that express K8/18 including liver, kidney, pan-
creas, salivary gland and intestine. No histologic abnor-
mality was noted in these organs and no differences were
noted in animal weight or keratin staining pattern (not
shown). In addition, hepatocyte viability after liver perfu-
sion was 
 
.
 
90% (
 
n
 
 5 
 
3 for each mouse line) for the TG2
and S52A lines, in contrast with the 
 
z
 
20% viability that is
seen in transgenic mice that express K18 arg89
 
®
 
cys that
results in disruption of the keratin filament network (25).
 
Basal and Post-Hepatectomy K18 Phosphorylation in 
TG2 and S52A Mice
 
We compared the overall basal K18 phosphorylation in
TG2 mice (which express WT K18) and S52A mice (which
express S52A
 
®
 
K18) using two-dimensional isoelectric
focusing/SDS-PAGE analysis. Previous tryptic phospho-
peptide mapping studies of K18 that was isolated from
cultured human HT29 cells showed that the major radiola-
beled K18 phosphopeptide corresponds to ser52 phosphor-
ylation (e.g., Fig. 2 
 
A
 
; reference 28). This is also the major
phosphopeptide in K18-transfected NIH-3T3 cells (Fig. 2
 
C
 
) and in K18 that is purified from TG2 
 
32
 
PO
 
4
 
-labeled
hepatocytes (Fig. 2 
 
B
 
). As shown in Fig. 3 
 
A
 
, WT K18 in
TG2 mice (
 
a
 
) or in HT29 cells (
 
d
 
) has 3 major isoforms
(isoforms no. 2 and no. 3 are not as well resolved in 
 
d
 
 as in
 
a
 
), whereas ser52
 
®
 
ala K18 in S52A mice (
 
b
 
) or in trans-
fected NIH-3T3 cells (not shown) lack isoform no. 3. The
assignment of the isoforms in Fig. 3 
 
A
 
 (
 
aÐd
 
) was confirmed
by mixing a 
 
1 
 
b and d 1 e samples followed by two-dimen-
sional gel analysis (not shown). This suggests that isoform
no. 3 (in this basal phosphorylation state as compared with
Figs. 5 and 6) corresponds to K18 that is primarily phos-
phorylated on ser52, and indicates that no significant com-
pensatory phosphorylation has taken place in vivo in the
transgenic mice. Isoform no. 3 also disappears upon treat-
ment of K8/18 immunoprecipitates from HT29 cells (Fig. 3
A, e) or from TG2 livers (not shown) with alkaline phos-
phatase, and immune reactivity to two anti-phospho-K18
antibodies is almost completely abolished upon alkaline
phosphatase treatment (Fig. 3 B). The precise nature of
K18 isoform no. 2 is not known, but it is not routinely re-
solved from isoform no. 3 (e.g., Fig. 3 A, c) and therefore
can be mistakenly considered as a phosphorylated isoform
whereas it is more likely to represent a unique posttransla-
tional modification. In support of this, isoform no. 2 does
not label in vivo upon metabolic labeling with 32PO4, is not
affected by alkaline phosphatase, and is not recognized by
two anti-phosphokeratin antibodies but is recognized by
an anti-pan-K18 antibody (data not shown but summa-
rized schematically in Fig. 3 A, f).
We used the post-hepatectomy liver regeneration mouse
model to examine changes in K18 phosphorylation and or-
ganization during mitosis, and the effect of the ser52®ala
mutation on liver regeneration. This is based on the mito-
sis-associated observed increase in K18 ser52 phosphory-
lation in cultured cells (37) and mice (27), and the appar-
ent role in filament reorganization in cultured cells upon
colcemid treatment of cells (23). As shown in Fig. 4 A,
minimal K18 incorporation of 32PO4 was observed in the
S52A mice, as compared with TG2 mice pre- and post-
hepatectomy, whereas changes in other phosphorylation
sites such as K18 ser33 or K8 ser73 were not significantly
affected. In addition, K8/18 phosphorylation in the S52A
mice appeared appropriate after partial hepatectomy, in
Figure 1. Characterization and expression of K18 S52A in trans-
genic mice. (A) Livers from transgenic mice that express WT K18
(TG2) or ser52®ala K18 (two independent transgenic lines
S52A1, S52A2) were isolated followed by K8/18 immunoprecipi-
tation using mAb L2A1 as described in Materials and Methods.
M1 and M2 correspond to independent mice that were used from
the indicated lines. Although mAb L2A1 recognizes human (h)
but not mouse (m) K18, the mouse K8 and K18 copolymerize
with hK18 in cells and therefore coprecipitate together. K8/18
precipitates were analyzed by SDS-PAGE followed by Coo-
massie staining, or were transferred to a PVDF membrane fol-
lowed by immunoblotting with Ab 3055 that recognizes human
phospho-ser52 of K18. Ab 3055 does not cross-react with the
mouse equivalent of human phospho-ser52 K18 since the context
of the sequence of the analogous phosphorylation site in mouse
K18 is slightly different (35, 48). (B) Livers similar to those used
in A were removed followed by high salt extraction of the keratin
fraction as described in Materials and Methods. Keratin extracts,
which include endogenous mouse and the transgene human K18
product, were analyzed by SDS-PAGE then Coomassie staining,
and blotted with Troma I antibody (which recognizes mouse K8)
or with rabbit antiÐhuman K8/18 antibody that also recognizes
mouse keratins.Ku et al. Keratin Phosphorylation and Liver Injury 2027
that an acidic shift in K8 and K18 isoforms was noted that
is consistent with K8/18 hyperphosphorylation (Fig. 4 C).
A similar shift was also noted in TG2 mouse K8/18 pre-
and post-hepatectomy (27 and data not shown). There was
no detectable difference in the ability of the S52A1 and
S52A2 mouse lines to regenerate their livers as compared
with TG2 mice (not shown), and a similar number of mi-
totic bodies were noted after partial hepatectomy (Fig. 4
B). Furthermore, no differences in keratin hepatocyte im-
munofluorescence staining were noted before or after par-
tial hepatectomy (not shown). This indicates that the in-
crease in K18 ser52 phosphorylation during mitosis does
not appear to play an obvious significant role in the fila-
ment organization or progression through mitosis in intact
animals.
Effect of K18 ser52 Phosphorylation in TG2 and S52A 
Mice on Susceptibility to Drug-induced Liver Injury
We tested the effect of two known hepatotoxins, griseoful-
vin (GF) and microcystin-LR (MLR), on TG2 and S52A
transgenic mice. These drugs were chosen because of their
dramatic toxic effect on the liver in association with K8/18
hyperphosphorylation (27, 52). TG2 and S52A mice were
fed GF mixed with the normal mouse diet. After 17 d, the
TG2 and S52A mice hyperphosphorylated their K18 simi-
larly, as reflected by two-dimensional gel analysis (Fig. 5
B). As noted previously, K18 ser52 phosphorylation does
not significantly change in TG2 mice after 17 d of GF feed-
ing (27; Fig. 5 A, lanes iÐl), but there is some ser52 dephos-
phorylation early on upon exposure of the TG2 mice to
Figure 2. Peptide mapping of human
K18 that is isolated from HT29 cells,
TG2 mouse livers or from NIH-3T3
transfected cells. Hepatocytes were
isolated from TG2 mice by liver perfu-
sion for primary culture, and NIH-3T3
were cotransfected with WT K8/18.
Hepatocytes, HT29 cells, or trans-
fected NIH-3T3 cells were labeled with
32PO4 followed by isolation of K8/18
immunoprecipitates then processing
for K18 phosphopeptide mapping as
described in Materials and Methods. Small x indicates location where sample was loaded. Arrows point to the ser52- or ser33-containing
phosphopeptides. Assignment of the ser52-containing phosphopeptide was done by mixing samples a 1 b or a 1 c then peptide mapping
(not shown). Assignment of pS33 was reported previously (30).
Figure 3. Dephosphorylation and two-dimensional gel
analysis of WT and ser52®ala K18 that are isolated from
HT29 cells and transgenic mice. K8/18 immunoprecipitates
(in duplicate) were obtained from HT29 cells or from
transgenic mice that overexpress WT or phosphorylation
mutant (S52A) K18. One of the immunoprecipitates was treated with calf in-
testine alkaline phosphatase (CIAP) as described in Materials and Methods,
while the duplicate was incubated with the dephosphorylation buffer alone.
(A) Immunoprecipitates were analyzed by isoelectric focusing in the horizon-
tal dimension followed by SDS-PAGE in the vertical dimension. The three
major K18 isoforms are numbered 1, 2, and 3. CIAP treatment abolishes iso-
form 3 in K8/18 precipitates from HT29 cell (e)  and from TG2 mice (not
shown). Note that depending on the separation conditions, K18 isoforms no. 2
and no. 3 do not resolve (as shown in c) or resolve somewhat poorly (as shown
in d). (B) K8/18 precipitates (6phosphatase treatment) that were obtained
from TG2 or S52A mice were analyzed by SDS-PAGE followed by immuno-
blotting with anti-pS52 or anti pS33 K18 antibodies. Note the near complete
dephosphorylation of pS33 and pS52 of K18. Blotting of similar K8/18 precipi-
tates from HT29 cells gave similar results (not shown).The Journal of Cell Biology, Volume 143, 1998 2028
GF (Fig. 5 A, lanes aÐh). However, maintaining a level of
K18 ser52 phosphorylation does appear to be important in
helping the hepatocyte cope with this drug-induced stress
since S52A mice had more significant necrosis than TG2
mice (Fig. 5 D and Table I). The necrotic cells are easily
discerned by their pale cytoplasmic color and virtual ab-
sence of nuclei. The mice had no GF-related mortality,
and the dramatic increase in liver weight and liver-related
Figure 4. Analysis of keratin phosphorylation in vivo in trans-
genic mice that express WT or S52A K18, before and after hepa-
tectomy. (A) TG2 and S52A mice were subjected to partial hepa-
tectomy as described in Material and Methods. After 66 h, the
regenerating livers were removed and a portion was fixed in 10%
formalin for the hematoxylin and eosin staining shown in B and
the remaining portion was used for metabolic labeling with 32PO4.
TG2 and S52A nonhepatectomized mouse livers were also simi-
larly labeled (250 mCi/ml, 5 h) followed by solubilization with 1%
Emp then immunoprecipitation of K8/18. Precipitates were ana-
lyzed by SDS-PAGE then Coomassie staining (a), autoradiogra-
phy (b), or by immunoblotting with: Ab 3055 which recognizes
K18 pS52 (c), Ab 8250 which recognizes K18 pS33 (d), or mAb
LJ4 which recognizes K8 pS73 (e). K8 ser73 phosphorylation was
shown previously to be a marker of mitotic cells in culture and in
regenerating mouse liver (40). Asterisk in panel a corresponds to
a degradation product of K8. (B) Livers from TG2 and S52A1
mice that underwent hepatectomy in A were stained with hema-
toxylin and eosin. Arrows indicate mitotic bodies. Livers from
S52A2 mice had a similar number of mitotic bodies post-hepatec-
tomy (not shown). (C) K8/18 immunoprecipitates were obtained
from S52A1 mice pre- and 72 h post-hepatectomy then examined
by two-dimensional gel analysis. Of note, similar K8/18 precipi-
tates that were obtained from S52A2 and TG2 mice (before and
after 72 h hepatectomy) showed a similar isoform pattern shift
except for the absence of isoform no. 3 in K18 from S52A2 mice
(not shown). Arrow in panel b highlights the increased intensity
of a K18 isoform, consistent with its increased phosphorylation.
Figure 5. Effect of GF on liver histology and keratin phosphory-
lation in TG2 and S52A mice. (A) K8/18 precipitates were ob-
tained from GF-fed TG2 mice after 2, 5, 8, or 17 d or from control
diet-fed mice. M1 and M2 correspond to independent mice that
were used from the indicated lines. The precipitates were sepa-
rated by SDS-PAGE followed by Coomassie staining or were
transferred to a PVDF membrane then blotted with anti-K18-
pS52 Ab. m and h indicate mouse and human keratins, respec-
tively. (B) K8/18 immunoprecipitates were obtained from 17-d
GF-fed TG2 and S52A1 mice, followed by two-dimensional gel
analysis. Note the similar shift in isoforms in a and b, and the sig-
nificant acidic shift for both relative to K8/18 that is isolated from
the non-GF-fed control mice (shown in Fig. 3 A). (C) K8/18 im-
munoprecipitates were obtained from TG2 and S52A mouse liv-
ers (6GF) as in A. Precipitates were blotted with Ab 8250 and
mAb LJ4 that recognize K18 pS33 and K8 pS73, respectively. (D)
Formalin-fixed livers from TG2 and S52A mice fed control diet
(2GF) or GF-containing diet (1GF) for 17 d were sectioned
then stained with hematoxylin and eosin.Ku et al. Keratin Phosphorylation and Liver Injury 2029
serum enzymes were similar when comparing TG2 with
S52A mice (not shown). Of note, S52A1 and S52A2 mice
had a very similar liver histologic response to GF (not
shown). No significant differences in K18 ser33 and K8
ser73 phosphorylation were noted between GF-fed TG2
and S52A mice (Fig. 5 C).
A comparison of the response of TG2 and S52A mice to
the hepatotoxin MLR was also carried out. As shown in
Fig. 6 A, MLR is associated with a dramatic increase
(threefold) in TG2 K18 ser52 phosphorylation as deter-
mined by immunoblotting with the 3055 Ab. K18 under-
goes significant hyperphosphorylation in TG2 and S52A
mice in response to MLR, as noted upon two-dimensional
gel analysis, although isoform no. 3 in S52A K18 is not as
prominent as in TG2 K18 (Fig. 6 C). Isoform no. 3 of K18
S52A (Fig. 6 C, b) likely represents unique phosphoryla-
tion (i.e., non-ser52) as compared with isoform no. 3 of
WT K18 (Fig. 6 C, a). In contrast to the GF model, S52A
mice manifested a higher increase in K8 ser73 and a mar-
ginal difference in K18 ser33 phosphorylation after MLR
exposure as compared with TG2 mice (Fig. 6 B). More im-
portantly, MLR administration resulted in significantly
more dramatic liver injury in the S52A mice as compared
with TG2 mice (Fig. 6 D and Table I). The more dramatic
liver injury noted in S52A mice involved all the MLR-
associated histologic features, including vacuolization, ne-
crosis, and hemorrhage (Table I) that have been well de-
scribed in TG2, K18 arg89®cys, and K8-null mice (52).
Necrotic pale-colored foci were primarily found near areas
of hemorrhage (Fig. 6 D). The results of GF and MLR ad-
ministration therefore indicate that blocking the phos-
phorylation of K18 ser52 in transgenic mice predisposes
them to drug-induced liver injury.
Discussion
This study uses the overexpression of a keratin site-spe-
cific phosphorylation mutant in transgenic mice to demon-
strate a physiologic role for keratin phosphorylation in
protecting hepatocytes from drug-induced liver injury.
Such a physiologic role is likely to apply to other IF pro-
teins. To our knowledge, this is the first example of using
transgenic mice to study the function of phosphorylation
in a protein. This approach is likely to be informative for
other proteins, particularly other IF proteins.
General Properties of K18
Phosphorylation and Keratin Filaments in the K18 
ser52®ala-expressing Transgenic Mice
As found in cultured cells, the K18 ser52-containing phos-
phopeptide is the major peptide that is labeled in trans-
genic mouse hepatocytes ex vivo (Fig. 2). Mutation of K18
ser52 followed by expression as a transgene product in
mice resulted in the expected expression pattern (Fig. 1)
without any evidence of compensatory phosphorylation of
the endogenous mouse K18 (or K8) or compensatory
phosphorylation of the human transgene K18 product at
other sites (Figs. 3 and 4). No obvious effect on keratin fil-
ament assembly, or on desmoplakin or plectin distribution
Table I. Comparison of Statistically Significant Differences in 
Phenotype Among GF- and MLR-treated TG2 and S52A Mice
GF Diet MLR Administration
Necrosis
score
Vacuolization
score
Hemorrhage
score
Alkaline
phosphatase
TG2 mice 10.3 6 8.2 0.30 6 0.48 0.60 6 0.70 267 6 23
S52A mice 23.7 6 28.3 1.33 6 0.50 1.60 6 0.84 166 6 17
p value 0.01 0.001 0.01 0.0001
The table shows only the parameters for which there was a statistically significant dif-
ference when comparing TG2 with S52A mice. No necrosis, vacuolization, or hemor-
rhage were noted in TG2 or S52A mice that were not given GF or MLR (not shown
but see Fig. 5). For each treatment (i.e., control, GF or MLR), 10 mice were analyzed.
Some of the standard deviations were high because of a few animals that had high pa-
rameters. Of note, alkaline phosphatase (U/L) was the only laboratory parameter that
showed a significant difference among the serum tests that were examined (see Mate-
rials and Methods). The alkaline phosphatase values in control TG2 and S52A mice
(n 5 8 from each line) were similar (131 6 6 and 123 6 6, respectively).
Figure 6. Effect of MLR on liver histology and keratin phos-
phorylation in TG2 and S52A mice. TG2 and S52A mice were
given MLR in saline, or saline alone, by intraperitoneal injection
followed by removal of the livers after 195 min as described in
Materials and Methods. (A) Liver fragments were homogenized
in Laemmli sample buffer or were solubilized in 1% Emp fol-
lowed by immunoprecipitation. Equal amounts (10 mg) of total
cell lysates from TG2 mice were separated by SDS-PAGE fol-
lowed by blotting with anti-K18 pS52 or anti-pS33 Ab, or with
anti-K8 antibody. A blot of nearly equal amounts of K8/18 pre-
cipitates (determined by Coomassie staining) gave a similar blot-
ting pattern (not shown). M1 and M2 correspond to independent
mice. (B)  K8/18 immunoprecipitates were obtained from TG2
and S52A mouse livers, after MLR administration as in A. Pre-
cipitates were blotted with Ab 8250 and mAb LJ4 that recognize
K18 pS33 and K8 pS73, respectively. (C) K8/18 immunoprecipi-
tates were obtained from MLR-administered TG2 and S52A
mice, followed by two-dimensional gel analysis. (D) Formalin-
fixed livers from MLR-administered TG2 and S52A mice were
sectioned then stained with hematoxylin and eosin.The Journal of Cell Biology, Volume 143, 1998 2030
was noted (not shown). We cannot exclude the possibility
that altered phenotypes in keratin or other potential asso-
ciated protein organization may have been obscured by
the normal endogenous mouse K18. Addressing such a
possibility may be feasible by breeding the S52A mice with
the K18-null mice that have been reported by Magin et al.
(42).
Analysis of the K18 isoforms by isoelectric focusing
strongly suggests that K18 has an acidic modification, the
nature of which remains to be defined. This modification
results in the generation of isoform no. 2 (Fig. 3) that does
not appear to be phosphorylated, based on resistance to
dephosphorylation, lack of labeling by 32PO4, and unde-
tectable reactivity with two anti-phospho-K18 antibodies
that recognize pS33 or pS52 (not shown). This isoform is
physiologic in that it is seen in K18 that is expressed in
mice and cultured human cells, is substoichiometric but
easily detectable when isoelectric focusing separation con-
ditions are favorable, and binds to a K18-specific antibody
(not shown) thereby making it unlikely that it could corre-
spond to another protein or to an alternate keratin or ker-
atin degradation product.
Although changes in keratin phosphorylation in re-
sponse to stress may appear at first glance to be global,
several points deserve mention. First, the increase in kera-
tin phosphorylation at multiple sites strongly suggests that
this response is likely to act at several levels. For example,
there appears to be distinct molecules of K18 that are
phosphorylated at either ser52 or ser33 in mouse liver (30)
thereby suggesting different functions. Indeed, one func-
tion for the K18 pS33 species is to bind 14-3-3 proteins and
in doing so affect the subcellular partitioning and orga-
nization of keratin filaments (30, 36). Second, although
changes in keratin phosphorylation occur at multiple sites
and increase in the same site via a variety of modalities,
some specificity and distinction is emerging. For example,
apoptosis increases K8 and K18 phosphorylation at multi-
ple sites (including K18 ser52) but does not affect K18
ser33 phosphorylation (28). In addition, studies in cultured
HT29 cells showed that heat stress increases K18 phosphor-
ylation primarily at non-ser52-containing sites, whereas
phosphatase inhibitors increase K18 phosphorylation pref-
erentially at ser52 (37).
Role of Keratin Phosphorylation in Providing 
Protection from Hepatotoxic Stress
The increase in K18 ser52 phosphorylation in response to
the phosphatase inhibitors okadaic acid in cultured cells
(37) and to MLR in TG2 mice (Fig. 6) raises at least four
roles to consider for this hyperphosphorylation: (a) a by-
stander noncontributory role, (b) a toxicity protective role
that in some ways may be considered similar to the induc-
tion of heat stress proteins, (c) a toxicity-promoting role,
or (d) any sequential combination of aÐc. The observed ef-
fect of increased susceptibility to liver injury in S52A as
compared with TG2 mice, upon exposure to GF or MLR,
provides in vivo evidence for the importance of K18 ser52
phosphorylation in modulating a protective role. The ef-
fect of the ser52 mutation is likely specific since other ma-
nipulations such as partial hepatectomy did not show a dif-
ference in liver regeneration between TG2 and S52A
mice. We speculate that the mechanism of protection in
the case of GF exposure is likely to be different than that
in MLR exposure, since the latter is associated with a sig-
nificant increase in K18 ser52 phosphorylation (Fig. 6). In
contrast, GF exposure does not significantly affect ser52
phosphorylation when analyzed after 17 d, but decreases it
slightly when analyzed after 5 d (Fig. 5). This suggests that
the protective role of ser52 phosphorylation in the case of
GF is likely to be indirect, as compared with MLR, and
that steady state ser52 phosphorylation may play a role in
initiating a cellular stress response in a fashion that could
entail initial dephosphorylation depending on the stressful
agent. Although the phenotype that we observe may sim-
ply be related to a structural defect that is caused by the
mutation rather than a phosphorylation event per se, such
a scenario is unlikely since the K18 ser52 mutant appears
to assemble normally and can apparently reorganize in the
context of mitosis without detectably affecting mitotic pro-
gression.
Previous clues to the importance of keratin and other IF
protein phosphorylation in helping cells cope with stress
are many, albeit correlative in nature. For example, in cul-
tured cells, heat stress or rotavirus infection (37, 38), apop-
tosis (28), alcohol (21), or exposure to anti-microtubule
agents (10) result in dramatic K8/18 hyperphosphoryla-
tion. Similarly, administration of GF to normal nontrans-
genic mice or transgenic normal mice that express WT
K18 (i.e., the TG2 mouse line) results in significant K8/18
hyperphosphorylation (27). In contrast, transgenic mice
that express a dominant negative K18 arg89®cys that re-
sults in keratin filament disruption are unable to hyper-
phosphorylate their keratins to the same extent as TG2
mice and are markedly more susceptible to GF-induced
liver injury (25, 27). Association of increased neurofila-
ment phosphorylation has also been correlated with stress
in PC12 cells (16) and with aging in rats (17).
The mechanism by which K18 ser52 phosphorylation
imparts protection from hepatotoxic stress now becomes
an important question to address. Several hypotheses can
be considered. For example, the K18 ser52 (and ser33)-
phosphorylated species are preferentially found in the sol-
uble and nonionic detergent extractable pool in cultured
cells (26, 47), and under basal conditions ser52 phosphory-
lation is highly dynamic and is the predominant site that is
labeled metabolically (Fig. 2). Therefore, the cellular loca-
tion of ser52-phosphorylated K18 in these compartments
may facilitate specific signaling events. Alternatively, ker-
atin phosphorylation may act as a phosphate sink to pro-
tect cells from excess kinase activity (32), or may provide a
phosphate reserve and help slow normal cellular processes
until the stress subsides (26). The availability of the S52A
transgenic mice should facilitate testing these hypotheses.
Potential Relevance of the GF and MLR Transgenic 
TG2 and S52A Mouse Models to Human Disease
The GF and MLR toxicity models tested herein have di-
rect relevance to hepatotoxicity in humans, and highlight
the potential for exploring K8/18 mutations in human idio-
pathic liver drug toxicity diseases. For example, a recently
reported outbreak of liver failure and subsequent death inKu et al. Keratin Phosphorylation and Liver Injury 2031
nearly 50% of patients undergoing hemodialysis, at a facil-
ity in Brazil, resulted from inadvertent microcystin-con-
taminated water, with detectable levels of microcystin in
serum and postmortem liver specimen (20). In addition,
GF is a commonly used drug for treatment of patients with
a variety of fungal infections (50). Despite the low GF tox-
icity level in humans versus animals, likely secondary to
differences in the porphyrogenic effect between humans
and mice (22), isolated cases of intrahepatic cholestasis
after GF administration have been reported (9). The
keratin mutation animal models that we have described
to date, namely the K18 arg89®cys (25) and the K18
ser52®ala herein, both have increased susceptibility to
drug-induced liver injury. Although to date only one cryp-
togenic liver disease patient with a K18 mutation that is as-
sociated with abnormal in vitro filament assembly has
been described (29), the animal model data (27, 41, this
study) do raise the possibility that K18 or K8 mutations
may present clinically as a predisposition to hepatotoxicity
upon specific environmental exposures. In this context, in-
ability of keratins to undergo hyperphosphorylation, ei-
ther directly (i.e., K18 ser52®ala mice) or indirectly (i.e.,
K18 arg89®cys mice), may provide one pathophysiologic
explanation for this predisposition.
The observed statistically significant lack of an increase
in serum alkaline phosphatase upon MLR exposure (Ta-
ble I), but not upon GF exposure (not shown), was also
seen in GF-fed mice that express K18 arg89®cys (z2,000
U/liter in GF-fed TG2 mice versus z460 in K18 arg89®
cys expressing mice; reference 27). In addition, K8-null
mice also have lower levels of serum alkaline phosphatase
as compared with control mice (4). The observed blunted
alkaline phosphatase response in S52A as compared with
TG2 mice suggests that keratin phosphorylation may play
a role in this effect. However, it remains to be determined
if this is a direct or indirect effect. To that end, changes in
keratin phosphorylation could interfere with alkaline
phosphatase secretion. Alternatively, the finding may sim-
ply reflect difference in necrosis such that situations of
extensive necrosis (i.e., GF-fed K18 arg89®cys or MLR-
administered S52A mice) result in limited spillage of the
apically localized membrane associated enzyme, whereas
situations of limited necrosis (i.e., GF-fed or MLR-admin-
istered TG2 mice) have the normal release of the enzyme.
Differentiating between these and other possibilities should
be feasible.
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